Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.33% | 53.30% | 47.12% | 34.42% | 23.35% |
| Total Depreciation and Amortization | -42.99% | -36.41% | -27.51% | -19.76% | -12.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.51% | -35.95% | -48.75% | -35.05% | -32.84% |
| Change in Net Operating Assets | -13.02% | -200.79% | -43.54% | -92.81% | 0.41% |
| Cash from Operations | 38.76% | 40.40% | 34.98% | 22.90% | 19.64% |
| Capital Expenditure | -107.32% | -75.61% | -75.61% | -53.19% | 76.02% |
| Sale of Property, Plant, and Equipment | -35.46% | -97.21% | 550.68% | 550.68% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.58% | -38.02% | -24.46% | -10.62% | -5.63% |
| Cash from Investing | -36.67% | -39.16% | -23.05% | -9.31% | -3.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.23% | -76.85% | -82.41% | -76.76% | -76.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -30.23% | -76.85% | -82.41% | -76.76% | -76.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.91% | -22.72% | 224.02% | 3,815.42% | 148.22% |